Human HepG2 and rat Fao hepatic-derived cell lines show different responses to ciprofibrate, a peroxisome proliferator: analysis by flow cytometry.
Peroxisome proliferators, and especially hypolipidemic drugs such as ciprofibrate, are known to be hepatocarcinogens in rodents, but their effect in humans is controversial. In an attempt to investigate the effects of ciprofibrate at a cellular level, the analysis of individual whole cells was performed by flow cytometry on samples from two hepatic-derived cell lines: the rat Fao cell line and the human HepG2 cell line. The increase of light scatter signals in rat Fao cells treated for 3 days with ciprofibrate at 250 microM was related to modifications of intrinsic cellular parameters, such as size and cytoplasmic granularity. Conversely, no variations appeared in human HepG2-treated cells. Moreover, the study of the cell cycle distribution of asynchronously growing cells showed an increase in the percentage of proliferative cells in Fao-treated cells, but not in HepG2-treated cells. In order to give a simultaneous assessment of changes in cellular parameters and cell metabolism, these flow cytometric experiments were completed with the measurements of the palmitoyl-CoA oxidase activity, used as a marker of peroxisome proliferation. The cellular modifications in the rat Fao cell line were accompanied by a great increase in this enzymatic activity, whereas the human HepG2 cell line, which failed to exhibit changes of cytometric data, presented no, or weak, increase in this oxidase activity. The cellular modifications observed in the rat Fao cell line may be related to the well-known hepatocarcinogenicity of ciprofibrate in rodents, whereas the absence of response of HepG2 cells is in favor of the noncarcinogenicity of this drug in humans. This report validates another methodological approach for the investigation of the safety of peroxisome proliferators in humans.
Passilly
P
P
LBMC, University of Burgundy, Dijon, France.
Jannin
B
B
Hassell
S J
SJ
Latruffe
N
N
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000201:enzymology / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D003594:Cytoplasmic Granules; D004273:DNA, Neoplasm / Q000032:analysis; D058607:Fibric Acids; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008027:Light; D008099:Liver / Q000166:cytology / Q000187:drug effects*; D008113:Liver Neoplasms / Q000201:enzymology / Q000473:pathology*; D008830:Microbodies / Q000187:drug effects* / Q000378:metabolism; D010088:Oxidoreductases / Q000378:metabolism; D051381:Rats; D012542:Scattering, Radiation; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D002995:Clofibric Acid; D010088:Oxidoreductases; C028427:palmitoyl CoA oxidase; C019304:ciprofibrate